References
- WHO Regional Office for Europe: Access to new medicines in Europe: technical review of policy initiatives and opportunities for collaboration and research. 2015 [http://www.euro.who.int/__data/assets/pdf_file/0003/273819/WHO-Medicines-Report-FINAL2015.pdf?ua=1].
- Vogler S, Habl C, Leopold C, Mazag J, Morak S, Zimmermann N: PHIS Hospital Pharma Report. Vienna: Pharmaceutical Health Information System (PHIS); 2010, http://whocc.goeg.at/Literaturliste/Dokumente/BooksReports/PHIS_Hospital%20Pharma_Report.pdf. Accessed 15 July 2015.
- Björkhem-Bergman L, Andersén-Karlsson E, Laing R, Diogene E, Melien O, Jirlow M, et al: Interface management of pharmacotherapy. Joint hospital and primary care drug recommendations. European Journal of Clinical Pharmacology 2013, 69(1):73–8.
- Vogler S, Zimmermann N, Habl C, Leopold C, Habimana K, Mantel-Teeuwisse A, et al: Which notions are applied to describe the cooperation mechanisms between hospital sector and primary care? Analysis of terminology 2013 http://whocc.goeg.at/Literaturliste/Dokumente/Posters/EAHP2013_PosterOHP084_TerminologyInterfaceManagement_final.pdf.
- Simoens S, Spinewine A, Foulon V, Paulus D: Review of the cost-effectiveness of interventions to improve seamless care focusing on medication. Int J Clin Pharm 2011, 33(6):909–917.
- Vogler S, Zimmermann N, Habl C, Leopold C, Dolinar E: OHP-073 Survey of Interface Management Measures Regarding Medicines. Eur J Hosp Pharm 2013, 20(Suppl 1):A161.
- Gustafsson LL, Wettermark B, Godman B, Andersén-Karlsson E, Bergman U, Hasselström J, et al: The ‘Wise List’– A Comprehensive Concept to Select, Communicate and Achieve Adherence to Recommendations of Essential Drugs in Ambulatory Care in Stockholm. Basic & Clinical Pharmacology & Toxicology 2011, 108(4):224–33.
- Herms S, Rutledge P: The Lothian Joint Formulary: overcoming the barriers to formulary success. Pharmacy in Practice 2002, 12(6):279–285.
- Garfield S: Advancing access to personalized medicine: a comparative assessment of European reimbursement systems. Personalized Medicine Coalition 2011 [http://www.personalizedmedicinecoalition.org/Userfiles/PMC-Corporate/file/pmc_bridgehead_issue_brief_european_reimbursement.pdf].
- Leopold C, Vogler S, Habl C, Mantel-Teeuwisse AK, Espin J: Personalised medicine as a challenge for public pricing and reimbursement authorities–A survey among 27 European countries on the example of trastuzumab. Health Policy 2013, 113(3):313–322.
- European Commission Directorate-General Health and Consumers: High Level Pharmaceutical Forum. High Level Pharmaceutical Forum 2005-2008. Conclusions and Recommendations. 2008, [http://bookshop.europa.eu/en/high-level-pharmaceutical-forum-2005-2008-pbND3008692/].
- European Commission: Platform on access to medicines in Europe 2013, [http://ec.europa.eu/growth/sectors/healthcare/competitiveness/corporate-responsibility/index_en.htm].
- Vogler S, Leopold C, Zimmermann N, Habl C, de Joncheere K: The Pharmaceutical Pricing and Reimbursement Information (PPRI) initiative–experiences from engaging with pharmaceutical policy makers. Health Policy and Technology 2014, 3(2):139–148.